Get the Stockscreener App
208.98
3.05%
-6.00
Overview
News
Price History
Option Chain
Financials
Why ABBV Down?
Discussions
Forecast
Dividend History
Abbvie Inc stock is traded at $208.98, with a volume of 2.71M.
It is down -3.05% in the last 24 hours and down -11.03% over the past month.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
See More
Previous Close:
$214.98
Open:
$213.99
24h Volume:
2.71M
Relative Volume:
0.39
Market Cap:
$369.48B
Revenue:
$61.16B
Net Income/Loss:
$4.19B
P/E Ratio:
88.50
EPS:
2.3614
Net Cash Flow:
$17.82B
1W Performance:
-1.27%
1M Performance:
-11.03%
6M Performance:
-11.89%
1Y Performance:
+1.58%
1-Day Range:
$207.71
$214.56
1-Week Range:
$207.71
$220.45
52-Week Range:
$164.39
$244.81
Abbvie Inc Stock (ABBV) Company Profile
Name
Abbvie Inc
Sector
Industry
Phone
(847) 932-7900
Address
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV vs LLY, JNJ, AZN, MRK
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
208.89 | 380.25B | 61.16B | 4.19B | 17.82B | 2.3614 |
LLY
Lilly Eli Co
|
936.06 | 852.73B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
243.54 | 587.99B | 94.19B | 26.80B | 19.70B | 11.05 |
AZN
Astrazeneca Plc
|
202.47 | 311.30B | 58.80B | 10.24B | 8.98B | 3.2788 |
MRK
Merck Co Inc
|
120.12 | 298.76B | 64.93B | 18.26B | 12.36B | 7.2751 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-25-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-08-26 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-10-25 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-04-25 | Downgrade | DZ Bank | Buy → Hold |
| Oct-14-25 | Downgrade | Erste Group | Buy → Hold |
| Oct-01-25 | Downgrade | HSBC Securities | Buy → Hold |
| Sep-17-25 | Upgrade | Berenberg | Hold → Buy |
| Aug-12-25 | Resumed | Piper Sandler | Overweight |
| Aug-07-25 | Upgrade | Daiwa Securities | Neutral → Outperform |
| May-14-25 | Downgrade | Citigroup | Buy → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-05-24 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Nov-22-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-04-24 | Upgrade | Argus | Hold → Buy |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jun-05-24 | Upgrade | HSBC Securities | Hold → Buy |
| May-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-29-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-18-23 | Downgrade | HSBC Securities | Buy → Hold |
| Dec-11-23 | Upgrade | Goldman | Neutral → Buy |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-30-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-20-23 | Resumed | UBS | Neutral |
| Sep-29-23 | Initiated | Raymond James | Outperform |
| Jul-25-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Apr-05-23 | Downgrade | Argus | Buy → Hold |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Feb-22-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-10-23 | Upgrade | SVB Securities | Underperform → Market Perform |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Nov-08-22 | Downgrade | Societe Generale | Buy → Hold |
| Aug-01-22 | Downgrade | Atlantic Equities | Overweight → Neutral |
| May-23-22 | Initiated | SVB Leerink | Underperform |
| May-06-22 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Feb-28-22 | Downgrade | UBS | Buy → Neutral |
| Feb-03-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-03-22 | Reiterated | Barclays | Equal Weight |
| Feb-03-22 | Reiterated | BofA Securities | Neutral |
| Feb-03-22 | Reiterated | Goldman | Neutral |
| Jan-13-22 | Initiated | Redburn | Buy |
| Jan-12-22 | Reiterated | BMO Capital Markets | Outperform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Nov-23-21 | Upgrade | Societe Generale | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-23-20 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Jun-09-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jun-02-20 | Upgrade | Argus | Hold → Buy |
| May-18-20 | Resumed | BofA/Merrill | Neutral |
| May-12-20 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-20 | Resumed | Morgan Stanley | Overweight |
| Apr-20-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-26-19 | Reiterated | Cowen | Outperform |
| Sep-26-19 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-27-19 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jun-26-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-28-19 | Initiated | Goldman | Neutral |
| Apr-29-19 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
View All
Abbvie Inc Stock (ABBV) Latest News
AbbVie Inc. $ABBV Shares Sold by Trust Co. of Vermont - marketbeat.com
Compagnie Lombard Odier SCmA Raises Holdings in AbbVie Inc. $ABBV - marketbeat.com
Banque Pictet & Cie SA Has $88.87 Million Stock Position in AbbVie Inc. $ABBV - marketbeat.com
What You Need to Know Ahead of AbbVie’s Earnings Release - Barchart.com
AbbVie Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Systemic Lupus Erythematosus Clinical Trial Pipeline Accelerates as 120+ Pharma Companies Rigorously Developing Drugs for Market Entry | DelveInsight - GlobeNewswire Inc.
Nisa Investment Advisors LLC Has $156 Million Stock Position in AbbVie Inc. $ABBV - MarketBeat
Moody Lynn & Lieberson LLC Has $43.98 Million Holdings in AbbVie Inc. $ABBV - marketbeat.com
Sarcopenia Treatments Market Is Going to Boom | AbbVie • Amgen • Pfizer • Novartis - openPR.com
AbbVie Inc. $ABBV Shares Bought by Capital Advisors Inc. OK - marketbeat.com
AbbVie Inc. $ABBV Shares Sold by Allspring Global Investments Holdings LLC - marketbeat.com
AbbVie (NYSE:ABBV) Shares Up 2%Time to Buy? - marketbeat.com
AbbVie Inc. stock rises Tuesday, still underperforms market - MarketWatch
Pfizer, Bain Must Litigate Cerevel Investors’ AbbVie Deal Suit - Bloomberg Law News
ABBV Stock Quote Price and Forecast - CNN
Bernstein Maintains AbbVie(ABBV.US) With Hold Rating, Maintains Target Price $225 - 富途牛牛
AbbVie Inc Stock (ABBV) Moved Up by 3.26% on Mar 31: Drivers Behind the Movement - TradingKey
/C O R R E C T I O N -- AbbVie/ - Investing News Network
Will AbbVie's Oncology Drugs Aid Top Line in 2026? - The Globe and Mail
Allergan Aesthetics Announces Fourth Annual, All-Access CoolMonth with Deals on CoolSculpting - Investing News Network
Allergan Aesthetics Announces Fourth Annual, All-Access CoolMonth with Deals on CoolSculpting® - AbbVie News Center
AbbVie to Host First-Quarter 2026 Earnings Conference Call - moomoo.com
Range Financial Group LLC Has $1.08 Million Holdings in AbbVie Inc. $ABBV - marketbeat.com
J. Safra Sarasin Holding AG Sells 36,172 Shares of AbbVie Inc. $ABBV - marketbeat.com
AbbVie Inc. $ABBV Holdings Lifted by Mn Services Vermogensbeheer B.V. - marketbeat.com
Financial Planning Hawaii Inc. Invests $2.90 Million in AbbVie Inc. $ABBV - marketbeat.com
AbbVie (NYSE:ABBV) Stock Price Up 1.8%Should You Buy? - marketbeat.com
AbbVie (ABBV) Gains As Market Dips: What You Should Know - Yahoo Finance
U.S. Naproxen Market Set for Dynamic Boom as Key Players AbbVie • Bayer • Amgen • Teva Pharmaceuticals - openPR.com
Gross profit of AbbVie, Inc. – BSESOF:4AB - TradingView
-0.83% for AbbVie stock as shares remain under key resistance levels - Traders Union
-0.83% for AbbVie stock as price remains below key moving averages - Traders Union
AbbVie Inc. $ABBV Stock Position Raised by TrueMark Investments LLC - MarketBeat
AbbVie, Inc. Trade Ideas — BSESOF:4AB - TradingView
Taxes of AbbVie, Inc. – BSESOF:4AB - TradingView
Waycross Partners Increases AbbVie Stock Holdings - National Today
Wedge Capital Management L L P NC Sells 6,019 Shares of AbbVie Inc. $ABBV - marketbeat.com
AbbVie Inc. $ABBV Stock Holdings Lifted by Waycross Partners LLC - marketbeat.com
Bell Bank Reduces Stake in AbbVie by 12.2% - National Today
Is AbbVie Inc. (ABBV) one of the debt free halal stocks to buy? - MSN
Bell Bank Has $12.09 Million Stake in AbbVie Inc. $ABBV - marketbeat.com
AbbVie Dermatology Data Sparks Questions On Growth Potential And Valuation - Yahoo Finance Singapore
Wealthcare Advisory Partners LLC Grows Stake in AbbVie Inc. $ABBV - marketbeat.com
Generate Investment Management Ltd Sells 49,224 Shares of AbbVie Inc. $ABBV - marketbeat.com
TABR Capital Management LLC Takes Position in AbbVie Inc. $ABBV - MarketBeat
Exchange Traded Concepts LLC Increases Stock Position in AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. Shares Purchased by Capital Investment Advisors - National Today
AbbVie Inc. $ABBV Shares Bought by Capital Investment Advisors LLC - marketbeat.com
AbbVie stock slips 0.83% as company highlights commitment to raising care standards at congress - Traders Union
Return on equity % of AbbVie, Inc. – BSESOF:4AB - TradingView
AbbVie: Strong 2026 Outlook, Expect Dividend Increases (NYSE:ABBV) - Seeking Alpha
Abbvie Inc Stock (ABBV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.77%
0.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):